Sanofi Bets on MRNA Vaccines Beyond COVID in $3.2B Translate Bio Deal

Sanofi Bets on MRNA Vaccines Beyond COVID in $3.2B Translate Bio Deal

Newsmax

Published

Sanofi has agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal, as it bets on next-generation mRNA vaccine technology beyond the COVID-19 pandemic, confirming a Reuters exclusive report. Sanofi said it would acquire all outstanding shares of Translate Bio...

Full Article